3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
270
Specimen Handling
259
pembrolizumab
235
Cyclophosphamide
220
Radiotherapy
208
Nivolumab
171
Cisplatin
162
Carboplatin
150
Biopsy
148
Radiosurgery
130
fludarabine
125
Blood Specimen Collection
117
Gemcitabine
113
Paclitaxel
111
Surveys and Questionnaires
109
Standard of Care
106
venetoclax
97
Dexamethasone
96
Bevacizumab
95
Radiation
88
Rituximab
84
Capecitabine
82
Cytarabine
79
Oxaliplatin
77
Doxorubicin
76
Drug Therapy
75
durvalumab
73
Ipilimumab
72
fludarabine phosphate
69
atezolizumab
69
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lasofoxifene
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled